Citadel Advisors
ORKA

Citadel Advisors’s Oruka Therapeutics ORKA Stock Holding History

Citadel Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$540K Buy
+11,000
New +$382K ﹤0.01% 9114
2025
Q4 		– Sell
-12,500
Closed -$240K – 14421
2025
Q3 		$240K Buy
+12,500
New +$185K ﹤0.01% 10852
2024
Q3 		– Sell
-1,842
Closed -$84.6K – 15459
2024
Q2 		$84.6K Sell
1,842
-2,716
-60% -$108K ﹤0.01% 11142
2024
Q1 		$97.4K Buy
4,558
+4,066
+826% +$80.9K ﹤0.01% 11394
2023
Q4 		$10K Sell
492
-400
-45% -$8.98K ﹤0.01% 13124
2023
Q3 		$21.5K Sell
892
-283
-24% -$6.93K ﹤0.01% 12571
2023
Q2 		$28.6K Buy
1,175
+450
+62% +$11.1K ﹤0.01% 12402
2023
Q1 		$17.3K Sell
725
-308
-30% -$8.12K ﹤0.01% 13164
2022
Q4 		$29.3K Buy
+1,033
New +$26.5K ﹤0.01% 12777
2022
Q2 		– Sell
-3,067
Closed -$85K – 14302
2022
Q1 		$85K Buy
3,067
+667
+28% +$16.5K ﹤0.01% 12428
2021
Q4 		$62K Buy
+2,400
New +$72.3K ﹤0.01% 13123
2021
Q2 		– Sell
-3,450
Closed -$151K – 14576
2021
Q1 		$151K Buy
+3,450
New +$181K ﹤0.01% 12026

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors's ORKA Position: Q1 2026 in Review

Citadel Advisors increased its Oruka Therapeutics (ORKA) stake by 39% in Q1 2026, buying an estimated $9.78M and bringing the position to 1,007,537 shares worth $49.4M. The position accounts for 0.01% of the portfolio, ranked #1372.

Citadel Advisors first reported a position in ORKA in Q2 2014 and has held it in 24 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Citadel Advisors held 1,007,537 shares of Oruka Therapeutics worth $49.4M as of Q1 2026.
  • Citadel Advisors bought 281,419 Oruka Therapeutics shares in Q1 2026, an estimated $9.78M.
  • Oruka Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1372 holding.
  • Citadel Advisors first reported a position in Oruka Therapeutics in Q2 2014 and has held it in 24 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.